Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | DPP4 | P27487 | 12/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18075665 | 1.00 | CYP19A1 (0.42) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL8203394 | 0.94 | DPP4 (0.46) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL1491553 | 0.94 | DPP4 (0.46) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL1491556 | 0.94 | DPP4 (0.46) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL723290 | 0.81 | CYP19A1 (0.47) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL13543466 | 0.81 | CYP19A1 (0.47) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL159982 | 0.81 | CYP19A1 (0.47) | CYP19A1EPHX1DPP4L3MBTL1DPP7 | |
| SCHEMBL16554167 | 0.79 | CYP19A1 (0.50) | CYP19A1EPHX1L3MBTL1 | |
| SCHEMBL770738 | 0.79 | CYP19A1 (0.50) | CYP19A1EPHX1L3MBTL1 | |
| SCHEMBL16373577 | 0.79 | CYP19A1 (0.50) | CYP19A1EPHX1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3549939-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| EP-3271349-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| EP-3271349-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146738-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | CYP19A1 3648/4885EPHX1 4148/4885DPP4 3530/4885 |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | CYP19A1 3648/4885EPHX1 4148/4885DPP4 3530/4885 |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | CYP19A1 3648/4885EPHX1 4148/4885DPP4 3530/4885 |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | CYP19A1 3648/4885EPHX1 4148/4885DPP4 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.